ClinicalTrials.Veeva

Menu

Pyrophosphate and Arterial Calcification in Chronic Kidney Disease (Predical)

C

Centre Hospitalier Universitaire de Nice

Status

Enrolling

Conditions

Chronic Kidney Diseases

Treatments

Other: Collect blood sample

Study type

Interventional

Funder types

Other

Identifiers

NCT04950439
19-API-02

Details and patient eligibility

About

Arterial calcifications start at early stages of chronic kidney disease (CKD) and are associated to cardiovascular mortality. Pyrophosphate (PPi) is an endogenous compound, which stops the mineralization process in bones and is expected to act at ectopic sites. In uremic rats, low PPi plasma levels are associated with high calcium content in the aorta and peritoneal administration of PPi blocks this process. People on maintenance dialysis or kidney transplant recipients have low plasma levels of PPi and show high scores of arterial calcification. The purpose is to determine the role of low PPi in the development of arterial calcifications in patients with CKD stage 3 or 4. To that aim, 252 patients with eGFR between 59 et 20 ml/min/1,73 m2 will be recruited and will be examined at baseline and three years later.

Enrollment

242 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • eGFR between 59 et 20 ml/min/1,73 m2 twice at three month interval

Exclusion criteria

  1. kidney transplantation
  2. acute inflammatory disease or active cancer

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

242 participants in 1 patient group

Myocardial CT
Other group
Description:
The investigator will collect the usual clinical history and data. Risk factors and cardiovascular events are identified. A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
Treatment:
Other: Collect blood sample

Trial contacts and locations

1

Loading...

Central trial contact

Favre Guillaume, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems